Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mineralys Therapeutics, Inc. (Nasdaq: MLYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor, through clinical development. As a clinical-stage biopharmaceutical company focused on hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other aldosterone-driven diseases, Mineralys uses SEC filings to report financial results, capital-raising activities and other material events.
Current and prospective investors can review Form 8-K filings where Mineralys reports quarterly financial results and corporate updates, as well as transactions such as underwritten public offerings of common stock and changes to at-the-market equity programs. These documents often reference the company’s clinical progress with lorundrostat, including pivotal trials like Launch-HTN and Advance-HTN, Phase 2 programs such as Explore-CKD and Explore-OSA, and steps toward a potential New Drug Application (NDA) with the U.S. Food and Drug Administration.
Over time, the filings set is expected to include annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks that elaborate on risk factors, liquidity, research and development spending, and the company’s dependence on the success of lorundrostat and key licensing arrangements. Investors may also monitor registration statements and prospectus supplements related to equity offerings, as reflected in referenced Form S-3 filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, such as trial-related disclosures, financing terms and forward-looking statements. Real-time updates from EDGAR, combined with tools to track items like material events and offering details, help users quickly understand how Mineralys Therapeutics’ regulatory and financial reporting aligns with its clinical and regulatory strategy for lorundrostat.
Mineralys Therapeutics, Inc. Chief Executive Officer Jon Congleton reported open-market sales of a total of 75,000 shares of the company’s Common Stock on March 31, 2026. The transactions were executed at weighted-average prices of $25.5006, $26.5385, and $27.0511 per share across multiple trades. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025. Following the transactions, Congleton directly holds 705,051 shares of Mineralys Therapeutics Common Stock.
Mineralys Therapeutics director Daphne Karydas reported an option exercise and share sale. She exercised stock options to acquire 3,000 shares of common stock at $12.02 per share, then sold 3,000 common shares in an open-market transaction at $25.00 per share.
After these transactions, she directly holds 6,200 shares of common stock and 41,000 stock options. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Mineralys Therapeutics reported a proposed sale of 3,000 shares of Common Stock under a Form 144 related to an exercise of employee stock options on 03/31/2026. The transaction is listed as a broker assisted cashless exercise through Merrill Lynch with aggregate value shown as $75,000.00.
Mineralys Therapeutics files a Form 144 reporting proposed sales of 75,000 shares of Common Stock. The filing lists an aggregate offering price of $1,970,520.69 and notes total shares outstanding of 82,399,478 as of 03/31/2026. It also discloses recent vesting of restricted share units (63,665 and 11,335 shares) and a related sale by Jon Congleton of 16,236 shares on 01/12/2026 for $529,639.51.
RA Capital–managed funds reported open-market purchases of Mineralys Therapeutics stock. On March 27, 2026, they bought 310,700 shares of common stock at a weighted average price of $23.67 per share. On March 30, 2026, they added 58,300 shares at a weighted average price of $24.16 per share.
Shares are held indirectly through RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P., with RA Capital Management, L.P. acting as investment manager. After these transactions, one fund held 5,825,521 shares as of March 30, 2026, while another related fund held 1,867,229 shares as of March 27, 2026.
Mineralys Therapeutics filed a Form 144 reporting proposed transactions in its common stock. The filing lists a broker-assisted cashless exercise of 417 shares on 03/17/2026 and a series of prior dispositions by David Rodman during Q1 2026, including a 192,715-share sale on 01/05/2026 for $6,749,100.06. The entries are presented as notices of securities to be sold and past sales by an affiliate.
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised stock options for 417 shares of common stock at $15.44 per share and on the same day sold 417 shares at $25.65 per share in an open-market trade. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. After these transactions, he directly owns 76,140 shares of Mineralys Therapeutics common stock, so the sale represents a small portion of his overall holdings.
Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales in Mineralys Therapeutics, Inc. common stock. On March 12–13, 2026, he exercised stock options for a total of 14,057 shares of common stock at exercise prices of $1.08, $10.20, and $14.25 per share. He then sold 20,406 shares in open-market transactions at weighted-average prices between approximately $25.77 and $27.92, executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he directly holds 76,140 shares of Mineralys Therapeutics common stock.
Mineralys Therapeutics reports multiple sales of Common Stock by David Rodman. The filings list a series of dispositions between 01/02/2026 and 03/12/2026, including transfers of 192,715 shares on 01/05/2026 and smaller tranches through March.
Transactions are characterized as cash or broker‑assisted cashless exercises and list per‑trade share counts and proceeds, indicating routine insider dispositions over the stated period.
Mineralys Therapeutics outlines its strategy to develop lorundrostat, an oral, highly selective aldosterone synthase inhibitor aimed at treating hypertension and related cardiorenal conditions such as CKD and OSA. The company has completed multiple Phase 2 and Phase 3 trials showing clinically meaningful blood pressure reductions and generally favorable safety.
In December 2025, Mineralys submitted a new drug application for lorundrostat for hypertension in combination with other antihypertensive drugs, which the FDA accepted with a PDUFA target action date of December 22, 2026. The report highlights strong Launch-HTN and Advance-HTN pivotal results, positive Explore-CKD data, mixed but BP‑positive Explore-OSA findings, substantial patent and licensing protections, and emphasizes that future performance and revenue depend heavily on successfully obtaining approval and commercializing lorundrostat while securing additional funding.